Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $26.44 Consensus Price Target from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRXGet Free Report) have been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $26.44.

A number of brokerages have issued reports on PCRX. Barclays boosted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. HC Wainwright boosted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Wall Street Zen raised Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Finally, Needham & Company LLC cut their target price on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, May 9th.

Check Out Our Latest Stock Report on PCRX

Pacira BioSciences Stock Up 0.3%

Shares of NASDAQ PCRX opened at $24.23 on Wednesday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -10.63 and a beta of 0.52. The company has a quick ratio of 1.99, a current ratio of 2.41 and a debt-to-equity ratio of 0.48. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $29.61. The business’s 50 day moving average is $25.47 and its two-hundred day moving average is $23.83.

Insiders Place Their Bets

In related news, SVP Lauren Riker sold 5,578 shares of the business’s stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the transaction, the senior vice president now owns 59,564 shares in the company, valued at approximately $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC grew its stake in shares of Pacira BioSciences by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 16,003 shares of the company’s stock worth $301,000 after purchasing an additional 3,710 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after purchasing an additional 70,307 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock worth $491,000 after purchasing an additional 794 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Pacira BioSciences during the fourth quarter worth $251,000. Finally, GAMMA Investing LLC grew its stake in shares of Pacira BioSciences by 5,187.8% during the first quarter. GAMMA Investing LLC now owns 91,796 shares of the company’s stock worth $2,281,000 after purchasing an additional 90,060 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

(Get Free Report

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Featured Stories

Analyst Recommendations for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.